Department of Pathology, Queen Alexandra Hospital, Portsmouth, UK.
J Clin Pathol. 2013 Jul;66(7):583-8. doi: 10.1136/jclinpath-2012-201339. Epub 2013 Mar 26.
Few studies have modelled the economics of thyroid FNA.
A simple spreadsheet economic model for delivery of thyroid fine needle aspiration (FNA) cytology is described using the UK Royal College of Pathologists' Classification for thyroid FNA which is based on The Bethesda System for Reporting Thyroid Cytopathology.
We show an estimated 27.8% cost treatment reduction per patient if low rates of non-diagnostic for cytological diagnosis (Thy 1) and neoplasm possible atypia/non-diagnostic (Thy 3a) are achieved, which require rapid onsite FNA adequacy assessment of aspiration samples. If we assume that the number of thyroid FNAs performed in the UK annually is around 500 per million, and the UK population is 62 million, this could save the UK National Health Service significant sums, as the additional cost per patient treated in this model varies from £781 for a scenario with ultrasound guided FNA and inclinic cell adequacy assessment to £998 where aspirates are taken in conventional fashion without any inclinic adequacy assessment.
This model makes a strong economic case for the introduction of rapid onsite assessment of thyroid FNA across cancer networks, to improve the diagnostic efficacy of thyroid FNA.
很少有研究对甲状腺细针抽吸术(FNA)的经济学进行建模。
使用英国皇家病理学家学院基于甲状腺细针抽吸细胞学报告的贝塞斯达系统(Bethesda System for Reporting Thyroid Cytopathology)的甲状腺 FNA 分类,描述了一个用于提供甲状腺细针抽吸细胞学的简单电子表格经济模型。
我们展示了如果能够实现较低的非诊断性细胞学诊断(Thy 1)和可能的非典型性/非诊断性肿瘤(Thy 3a)的比例,那么每位患者的治疗成本估计会降低 27.8%,这需要快速现场评估抽吸样本的 FNA 充分性。如果我们假设英国每年进行的甲状腺 FNA 数量约为每百万 500 例,而英国人口为 6200 万,那么这将为英国国民保健制度节省大量资金,因为在该模型中,每位治疗患者的额外成本从超声引导 FNA 和门诊细胞充分性评估的 781 英镑到不进行任何门诊充分性评估的常规方式抽吸的 998 英镑不等。
该模型为在癌症网络中引入甲状腺 FNA 的现场快速评估提供了强有力的经济依据,以提高甲状腺 FNA 的诊断效果。